scholarly journals Raloxifene Lowers Serum Calcium and Markers of Bone Turnover in Postmenopausal Women with Primary Hyperparathyroidism

2003 ◽  
Vol 88 (3) ◽  
pp. 1174-1178 ◽  
Author(s):  
Mishaela R. Rubin ◽  
Kristen H. Lee ◽  
Donald J. McMahon ◽  
Shonni J. Silverberg
Keyword(s):  
Primary Hyperparathyroidism ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Serum Calcium ◽  
Markers Of Bone Turnover

scholarly journals The comparative efficiency of denosumab treatment in patients with postmenopausal osteoporosis, primary hyperparathyroidism and glucocorticoid-induced osteoporosis in real clinical practice

2021 ◽  
Vol 23 (1) ◽  
pp. 4-13
Author(s):  
Liudmila Ya. Rozhinskaya ◽  
Sofya A. Gronskaia ◽  
Elizaveta O. Mamedova ◽  
Zhanna E. Belaya ◽  
Galina A. Melnichenko
Keyword(s):  
Clinical Practice ◽  
Femoral Neck ◽  
Primary Hyperparathyroidism ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Serum Calcium ◽  
T Score ◽  
Median Increase ◽  
Male To Female ◽  
Denosumab Treatment

Background: Denosumab is a highly effective and safe first-line treatment for osteoporosis. Primary hyperparathyroidism is a prevalent condition found in patients with osteoporosis. However, data regarding effectiveness of denosumab treatment in patients with PHPT are scarce. Aims: To estimate the comparative effects of denosumab to treat postmenopausal osteoporosis (PMO) and osteoporosis caused by primary hyperparathyroidism (PHPT) or glucocorticoid-induced osteoporosis (GIOP) in postmenopausal women in routine clinical practice. Materials and methods: Retrospective study based on the medical card records. Patients over 50 years of age with verified osteoporosis (based on bone mineral density (BMD) T-score ≤ -2.5 SD and/or low-trauma fracture), who had at least 3 denosumab injections were included in the study. Results: 162 patients were included and divided into three groups according to the etiology of osteoporosis. The first group consisted of postmenopausal women with osteoporosis (PMO) [(n=85); median age 70 [64;78]]. Patients with glucocorticoid-induced osteoporosis (GIOP) were enrolled in the second group [(n=16); male to female ratio =1:15; median age 60 [57,8; 66,3]]. The third group consisted of patients with PHPT and osteoporosis [(n=61); male to female=2:59; median age 68 [63; 75]]. Among all patients, denosumab treatment significantly increased BMD and decreased serum levels of calcium and CTx compared with baseline. PMO: the median increase in BMD according to the T-score was L1-L4 0,6 (p<0,001), femoral neck 0,2 (p<0,001); serum calcium -0,04 (p=0,004). PHPT: the median increase in BMD according to the T-score was L1-L4 0,6 (p<0,001), femoral neck 0,2 (p<0,001); radius 33% 0,25 (p=0,002), serum calcium -0,04 (p<0,001). In patients with GIOP, denosumab increased BMD in the lumbar spine L1-L4 0,5 (p=0,004). There was no difference in BMD increase or in levels of bone turnover suppression between the groups. A marked decline in levels of serum calcium was noted among patients with GFR less than 60 ml / min / 1.73 m2 (median Δ Са serum=0,24 p<0,001), compared to patients without CKD (median Δ Са serum=0,08 p<0,001).Conclusion: Denosumab treatment is similarly effective for increasing BMD and decreasing bone turnover markers in patients with PMO and PHPT among postmenopausal women. The hypocalciemic effect of denosumab is most significant in subjects with PHPT.

scholarly journals A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women1

2000 ◽  
Vol 85 (6) ◽  
pp. 2197-2202
Author(s):  
Karen M. Prestwood ◽  
Michele Gunness ◽  
Douglas B. Muchmore ◽  
Yili Lu ◽  
Mayme Wong ◽  
...  
Keyword(s):  
Lumbar Spine ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Biochemical Markers ◽  
Mineral Density ◽  
Bone Formation Rate ◽  
Markers Of Bone Turnover ◽  
Bone Biopsies ◽  
Hip Bmd ◽  
Total Body

Raloxifene HCl, a selective estrogen receptor modulator, has been shown to increase bone mineral density (BMD) and decrease biochemical markers of bone turnover in postmenopausal women without stimulatory effects on the breast and uterus. However, it is not known whether the changes in BMD and bone turnover are associated with changes at the tissue level, nor how changes with raloxifene compare with estrogen. In this randomized, double blind study, we evaluated the effects of raloxifene (Evista, 60 mg/day) or conjugated equine estrogens (CEE; Premarin, 0.625 mg/day) on bone architecture, bone turnover, and BMD. Iliac crest bone biopsies were obtained at baseline and at the end of the study after double tetracycline labeling and were analyzed for standard histomorphometric indexes. Serum and urinary biochemical markers of bone turnover were measured at baseline and at 4, 10, 18, and 24 weeks of treatment. Total body, lumbar spine, and hip BMD were measured at baseline and at the end of the study by dual energy x-ray absorptiometry. Activation frequency and bone formation rate/bone volume were significantly decreased from baseline in the CEE, but not in the raloxifene, group. Bone mineralization did not change in either group. Most markers of bone resorption and formation decreased in both groups, but to a greater degree in the CEE group (P &lt; .05). Total body and lumbar spine BMD increased from baseline in both groups, with a greater increase in the CEE group (P&lt; 0.05). Hip BMD significantly increased from baseline in the raloxifene group, but the change was not different from that in the CEE group. These results suggest that raloxifene reduces bone turnover and increases bone density, although to a lesser extent than CEE. Thus, raloxifene is an alternative to CEE for the prevention and treatment of osteoporosis in postmenopausal women.

Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women

2006 ◽  
Vol 24 (4) ◽  
pp. 314-318 ◽  
Author(s):  
Janne Komi ◽  
Kari S. Lankinen ◽  
Michael DeGregorio ◽  
Jorma Heikkinen ◽  
Seppo Saarikoski ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Postmenopausal Women ◽  
Biochemical Markers ◽  
Markers Of Bone Turnover

Association Between Female Sex Hormones and Biochemical Markers of Bone Turnover in Peri- and Postmenopausal Women

1998 ◽  
Vol 62 (5) ◽  
pp. 388-394 ◽  
Author(s):  
P. Peichl ◽  
A. Griesmacher ◽  
P. Pointinger ◽  
R. Marteau ◽  
W. Hartl ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Postmenopausal Women ◽  
Sex Hormones ◽  
Biochemical Markers ◽  
Female Sex ◽  
Female Sex Hormones ◽  
Markers Of Bone Turnover

EFFECT OF NORETHINDRONE ACETATE ON HORMONE LEVELS AND MARKERS OF BONE TURNOVER IN ESTROGEN-TREATED POSTMENOPAUSAL WOMEN

2001 ◽  
Vol 27 (4) ◽  
pp. 473-480 ◽  
Author(s):  
Olufunmilayo A. Onobrakpeya ◽  
Pamela M. Fall ◽  
Alice Willard ◽  
Priya Chakravarthi ◽  
Adrienne Hansen ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Postmenopausal Women ◽  
Hormone Levels ◽  
Markers Of Bone Turnover ◽  
Norethindrone Acetate
Sign in / Sign up

Export Citation Format

Share Document